Close to three-quarters of ovarian cancer cases are frequently diagnosed at an advanced stage, with more than 70% of them failing to respond to primary therapy and relapsing within 5 years. There is an urgent need to identify strategies for early detection of ovarian cancer recurrence, which may lead to earlier intervention and better outcomes. A customized magnetic bead-based 8-plex immunoassay was evaluated using a Bio-Plex 200 Suspension Array System. Target protein levels were analyzed in sera from 58 patients diagnosed with advanced ovarian cancer (including 34 primary and 24 recurrent tumors) and 46 healthy controls. The clinical performance of these biomarkers was evaluated individually and in combination for their ability to detect recurrent ovarian cancer. An 8-plex immunoassay was evaluated with high analytical performance suitable for biomarker validation studies. Logistic regression modeling selected a two-marker panel of CA-125 and VCAM-1 that improved the performance of CA-125 alone in detecting recurrent ovarian cancer (AUC: 0.813 versus 0.700). At a fixed specificity of 83%, the two-marker panel significantly improved sensitivity in separating primary from recurrent tumors (70.8% versus 37.5%, P = 0.004), demonstrating that VCAM-1 was significantly complementary to CA-125 in detecting recurrent ovarian cancer. A two-marker panel of CA-125 and VCAM-1 showed strong diagnostic performance and improvement over the use of CA-125 alone in detecting recurrent ovarian cancer. The experimental results warrant further clinical validation to determine their role in the early detection of recurrent ovarian cancer.

中文翻译：

---

VCAM-1 补充 CA-125 检测复发性卵巢癌

近四分之三的卵巢癌病例经常在晚期被诊断出来，其中超过 70% 对主要治疗没有反应，并在 5 年内复发。迫切需要确定早期检测卵巢癌复发的策略，这可能会导致更早的干预和更好的结果。使用 Bio-Plex 200 悬浮阵列系统评估基于定制磁珠的 8 重免疫测定。对 58 名诊断为晚期卵巢癌的患者（包括 34 名原发性肿瘤和 24 名复发性肿瘤）和 46 名健康对照者的血清中的靶蛋白水平进行了分析。对这些生物标志物的临床表现进行了单独和组合评估，以评估其检测复发性卵巢癌的能力。8 重免疫测定法经过评估，具有适合生物标志物验证研究的高分析性能。Logistic 回归模型选择了 CA-125 和 VCAM-1 的双标记物组，提高了单独使用 CA-125 检测复发性卵巢癌的性能（AUC：0.813 与 0.700）。在固定特异性为 83% 时，双标记物组合显着提高了分离原发性肿瘤和复发性肿瘤的灵敏度（70.8% 对比 37.5%，P = 0.004），表明 VCAM-1 在检测复发性卵巢肿瘤方面与 CA-125 显着互补癌症。CA-125 和 VCAM-1 两种标记物组合在检测复发性卵巢癌方面表现出强大的诊断性能，并且比单独使用 CA-125 有所改善。